International Clinical Trials

@IntClinTrials

International Clinical Trials is a specialist journal designed to provide global coverage of topics pertinent to the clinical trials sector.

London
Vrijeme pridruživanja: rujan 2014.

Tweetovi

Blokirali ste korisnika/cu @IntClinTrials

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @IntClinTrials

  1. Prikvačeni tweet

    ICT November has arrived, tackling the complex world of site monitoring and risk-based approaches, innovative trial design, and dementia research – featuring articles from and : (Subscribe: )

    Poništi
  2. Professor Clive Ballard at the University of Exeter Medical School and Dr Dawie Wessels examine how patient registries can improve the recruitment of dementia clinical trials: (Subscribe: )

    Poništi
  3. Ricky Lakhani speaks with ICT about the benefits and challenges of designing an effective trial management system: (Subscribe: )

    Poništi
  4. Dr Tracy Goeken examines the benefits of conducting clinical trials in Asia Pacific for its vast patient population: (Subscribe: )

    Poništi
  5. Dr Pavle Vukojevic, Dr Milan Marinkov, and Dr Jovana Vlajkovic-Josic present their formula for success in improving recruitment and streamlining rare disease trials: (Subscribe: )

    Poništi
  6. proslijedio/la je Tweet
    10. pro 2019.

    Read ' recent article on " & : A Decentralised Ecosystem" for insights on the topic from ICON's Ian O’Shaughnessy

    Poništi
  7. proslijedio/la je Tweet
    5. pro 2019.

    Nurdan Citamak at Faubel Pharma Services writes on IoT applications and how supply chain can modernise... (Subscribe here: )

    Poništi
  8. Professor Clive Ballard at the University of Exeter Medical School and Dr Dawie Wessels at AES () discuss new approaches to dementia prevention and the benefits of patient registries: (Subscribe: )

    Poništi
  9. Shani McCoy at Berkshire Healthcare Foundation Trust assesses the factors that contribute to patient burden in dementia research: (Subscribe: )

    Poništi
  10. proslijedio/la je Tweet
    28. stu 2019.

    What is the future of medicinal cannabis? 's Callum McGuinn writes on the subject in the October issue of EBR. Read the article here: and subscribe here:

    Poništi
  11. François Torche addresses the importance of more optimised monitoring approaches in clinical data science: (Subscribe: )

    Poništi
  12. New barriers need to be addressed to accelerate cell therapy drug approvals, explains HemaCare’s Dominic Clarke and Brad N Taylor: (Subscribe: )

    Poništi
  13. proslijedio/la je Tweet
    12. stu 2019.

    Ruth Roberts from writes on the potential of artificial intelligence on the latest issue of EBR, read the article here: and subscribe here:

    Poništi
  14. The Pharma industry is more often now caught in the dichotomy between functional and full service provision, explains Daniel Chapple : (Subscribe: )

    Poništi
  15. For Susan Najjar at , a Covance company, it’s important to ensure that business strategies are centred on the patient: (Subscribe: )

    Poništi
  16. proslijedio/la je Tweet
    5. stu 2019.

    The relationships between universities and the pharmaceutical industry are changing, but are the changing for the better? Chiesi discuss… (Subscribe here: )

    Poništi
  17. proslijedio/la je Tweet
    5. stu 2019.

    Gary Skarja at shares his knowledge on monoclonal antibodies in the EBR October article 'Next Generation Purification of Monoclonal Antibodies. You can read it here: and subscribe to EBR here:

    Poništi
  18. PIPA’s Emma Boulton and Dora Amene examine the legislation regulations involved in data compliance for pharmacovigilance: (Subscribe: )

    Poništi
  19. proslijedio/la je Tweet
    29. lis 2019.

    Patrick Liddy writes on 5 ways augmented reality will help the manufacturing process... (Subscribe here: )

    Poništi
  20. PharSafer’s Graeme Ladds evaluated the responsibilities of sponsors and licence holders in pharmacovigilance outsourcing: (Subscribe: )

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·